TANVEX BioPharma, the biosimilar-focused company, today announced that its Board of Directors has appointed Stephen Lam as the company's CEO.
Lam succeeds Henry Chen, who remains Chairman until the closing of Tanvex's strategic alliance with Bora Pharmaceuticals Co Ltd.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Sep 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Sep 24
